- Home
- ACAD vs GBDC Comparison
ACAD vs GBDC Comparison
Compare ACAD & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- GBDC
- Stock Information
- Founded
- ACAD 1993
- GBDC 2009
- Country
- ACAD United States
- GBDC United States
- Employees
- ACAD N/A
- GBDC N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- GBDC Finance: Consumer Services
- Sector
- ACAD Health Care
- GBDC Finance
- Exchange
- ACAD Nasdaq
- GBDC Nasdaq
- Market Cap
- ACAD 3.8B
- GBDC 4.0B
- IPO Year
- ACAD 2004
- GBDC 2010
- Fundamental
- Price
- ACAD $20.98
- GBDC $15.20
- Analyst Decision
- ACAD Buy
- GBDC Buy
- Analyst Count
- ACAD 18
- GBDC 4
- Target Price
- ACAD $27.71
- GBDC $15.50
- AVG Volume (30 Days)
- ACAD 2.1M
- GBDC 1.5M
- Earning Date
- ACAD 08-05-2025
- GBDC 08-04-2025
- Dividend Yield
- ACAD N/A
- GBDC 10.34%
- EPS Growth
- ACAD N/A
- GBDC N/A
- EPS
- ACAD 1.37
- GBDC 1.18
- Revenue
- ACAD $996,283,000.00
- GBDC $830,269,000.00
- Revenue This Year
- ACAD $13.39
- GBDC $21.93
- Revenue Next Year
- ACAD $10.59
- GBDC N/A
- P/E Ratio
- ACAD $15.33
- GBDC $12.84
- Revenue Growth
- ACAD 22.42
- GBDC 28.08
- 52 Week Low
- ACAD $13.40
- GBDC $12.68
- 52 Week High
- ACAD $25.23
- GBDC $16.08
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- GBDC 63.03
- Support Level
- ACAD $20.75
- GBDC $14.23
- Resistance Level
- ACAD $23.09
- GBDC $14.80
- Average True Range (ATR)
- ACAD 0.78
- GBDC 0.24
- MACD
- ACAD -0.20
- GBDC 0.07
- Stochastic Oscillator
- ACAD 9.83
- GBDC 95.28
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.